Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)

被引：2

作者：

Bahlis N.J. ^{[1
]}

Costa L.J. ^{[2
]}

Facon T. ^{[3
]}

Harousseau J.-L. ^{[4
]}

Manier S. ^{[3
]}

Perrot A. ^{[5
]}

Touzeau C. ^{[6
]}

Mohty M. ^{[7
]}

机构：

[1] University of Calgary, Calgary, AB

[2] Division of Hematology/Oncology, O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham, University of Alabama at Birmingham, Birmingham, AL

[3] University Hospital of Lille, University of Lille, Lille

[4] Institut de Cancerologie de l’Ouest, Centre René Gauducheau, Nantes-St Herblain

[5] Service d’Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse

[6] Department of Hematology, University Hospital Hôtel-Dieu, Nantes

[7] Sorbonne University, Service d’Hématologie Clinique Et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, INSERM UMRs938, Paris

来源：

Clinical Hematology International | 2023年 / 5卷 / 2-3期

关键词：

Immumotherapy; Multiple myeloma; Stem cell transplantation;

D O I：

10.1007/s44228-023-00036-8

中图分类号：

学科分类号：

摘要：

This round table discussion organized by the International Academy for Clinical Hematology (IACH) was dedicated to the 19th annual meeting of the International Myeloma Society (IMS), which was held in Los Angeles between the 25th and 27th August 2022. After some key meetings of the discipline of the field of clinical hematology, the IACH organizes regular round table discussion in order to summarize the flow of information and get the opinion of a panel of experts and the key take-home messages. As part of this discussion, the panellists debated 6 key topics: disease monitoring, management of high-risk multiple myeloma (MM), induction for newly-diagnosed MM, management of relapsed MM, immune reconstitution, and vaccination and cellular therapy in MM. © 2023, The Author(s).

引用

页码：112 / 121

页数：9

共 37 条

[1]

Costa L.J., Chhabra S., Callander N.S., Et al., Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted consolidation and treatment cessation. Final primary end point analysis of the Master trial, Blood, 138, (2021)

[2]

Minimal Residual Disease Adapted Strategy (MIDAS) Krd-Isatuximab: Frontline Therapy for Patients Eligible for Autologous Stem Cell Transplantation less than 66 Years

[3]

a Prospective Study

[4]

San-Miguel J., Avet-Loiseau H., Paiva B., Kumar S., Dimopoulos M.A., Facon T., Et al., Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE, Blood, 139, 4, pp. 492-501, (2022)

[5]

Avet-Loiseau H., Lauwers-Cances V., Corre J., Moreau P., Attal M., Munshi N.C., Minimal residual disease in multiple myeloma: final analysis of the IFM2009 trial, Blood, 130, pp. 435-445, (2017)

[6]

Oliva S., Hofste op Bruinink D., RIhova L., Spada S., van der Holt B., Troia R., Et al., Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial, J Clin Oncol, 35, (2017)

[7]

Zweegman S., Usmani S.Z., Chastain K., Carey J., Ren K., Smith E., Et al., Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS), J Clin Oncol, 37, (2019)

[8]

Orlowski R.Z., Goldschmidt H., Cavo M., Martin T.G., Paux G., Oprea C., Facon T., Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM), J Clin Oncol, 36, (2018)

[9]

Facon T., Lee J.H., Moreau P., Niesvizky R., Dimopoulos M., Hajek R., Et al., Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma, Blood, 133, 18, pp. 1953-1963, (2019)

[10]

Kumar S.K., Jacobus S.J., Cohen A.D., Weiss M., Callander N., Singh A.K., Et al., Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial, Lancet Oncol, 21, 10, pp. 1317-1330, (2020)

← 1 2 3 4 →